A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bempegaldesleukin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Nivolumab/relatlimab (Primary) ; Relatlimab (Primary) ; Zanzalintinib (Primary)
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Acronyms STELLAR-002
Sponsors Exelixis

02 Apr 2025 Planned End Date changed from 1 May 2026 to 28 Jun 2030.
02 Apr 2025 Planned primary completion date changed from 1 Feb 2026 to 28 Jun 2030.
02 Apr 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com